Oral vinorelbine: a narrative review
Carole Farrell Research fellow, The Christie Hospital NHS Foundation Trust, Manchester, England
Victoria Harmer Macmillan consultant nurse (breast), Imperial College London, England
Mark Foulkes Nurse consultant/lead cancer nurse, Royal Berkshire NHS Foundation Trust, Reading, England
Tom Allum Macmillan patient information and support service manager, Imperial College London, England
The incidence of many cancers is increasing; coupled with a decline in mortality rates (Cancer Research UK 2017a) this translates to more people living with and beyond their cancer diagnosis. Cancer is generally viewed as a chronic condition and this is often true for many diagnosed with metastatic breast cancer (MBC). In advanced/metastatic disease, there is a greater emphasis on promoting patients’ quality of life, and oral treatments can have additional benefits for patients, such as ease of administration, potentially reduced toxicities and fewer hospital visits. Oral vinorelbine was licenced in 2006 for the treatment of non-small cell lung cancer and MBC. This paper provides a narrative review of evidence from clinical trials, outlining the development and clinical application of oral vinorelbine, including implications for clinical practice and patient care.
Cancer Nursing Practice.
17, 2, 25-33.
Conflict of interest
This article has been subject to external double-blind review and has been checked for plagiarism using automated software
Write for us
For information about writing for RCNi journals, contact email@example.com
For author guidelines, go to rcni.com/writeforus
Received: 14 July 2017
Accepted: 11 January 2018
Want to read more?
Already subscribed? Log in
Unlock full access to RCNi Plus today
Save over 50% on your first 3 months
Your subscription package includes:
- Unlimited online access to all 10 RCNi Journals and their archives
- Customisable dashboard featuring 200+ topics
- RCNi Learning featuring 180+ RCN accredited learning modules
- RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests
Alternatively, you can purchase access to this article for the next seven days. Buy now